Patents by Inventor Richard Pracitto
Richard Pracitto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8536338Abstract: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: GrantFiled: May 14, 2012Date of Patent: September 17, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Richard Pracitto, John F. Kadow, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, Andrew Nickel, Kyle E. Parcella, Kap-Sun Yeung, Louis S. Chupak
-
Publication number: 20130178468Abstract: Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: September 7, 2012Publication date: July 11, 2013Inventors: Joseph P. Vacca, John S. Wai, Linda S. Payne, Richard C. A. Isaccs, Wei Han, Melissa Egbertson, Richard Pracitto
-
Patent number: 8324212Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: GrantFiled: February 22, 2011Date of Patent: December 4, 2012Assignee: Bristol-Myers Squibb CompanyInventors: John F. Kadow, Richard Pracitto
-
Patent number: 8293909Abstract: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: GrantFiled: March 9, 2010Date of Patent: October 23, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Richard Pracitto, John F. Kadow, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, Andrew Nickel, Kyle E. Parcella, Kap-Sun Yeung, Louis S. Chupak
-
Publication number: 20120232099Abstract: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: ApplicationFiled: May 14, 2012Publication date: September 13, 2012Inventors: Richard Pracitto, John F. Kadow, John A. Bender, Brett R. Beno, Katherine A. Grant-Young, Ying Han, Piyasena Hewawasam, Andrew Nickel, Kyle E. Parcella, Kap-Sun Yeung, Louis S. Chupak
-
Patent number: 8242280Abstract: The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.Type: GrantFiled: April 10, 2008Date of Patent: August 14, 2012Assignee: SGX Pharmaceuticals, Inc.Inventors: Chixu Chen, Brian Eastman, Andreas Gosberg, Stefan N. Gradl, Gavin Hirst, Stephanie Hopkins, Khanh Thi Tuong Nguyen, Richard Pracitto, Paul E. Sprengeler, Ruo W. Steensma
-
Patent number: 8198449Abstract: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: GrantFiled: August 28, 2009Date of Patent: June 12, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Richard Pracitto, John F. Kadow, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, Andrew Nickel, Kyle E. Parcella, Kap-Sun Yeung, Louis S. Chupak
-
Publication number: 20120046294Abstract: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: ApplicationFiled: February 22, 2011Publication date: February 23, 2012Inventors: John F. Kadow, Richard Pracitto
-
Patent number: 7960417Abstract: The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.Type: GrantFiled: February 17, 2006Date of Patent: June 14, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Steven P. Govek, Jean-Michel Vernier, Theodore Kamenecka, John H. Hutchinson, Richard Pracitto
-
Publication number: 20100184800Abstract: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: ApplicationFiled: March 9, 2010Publication date: July 22, 2010Inventors: Richard Pracitto, John F. Kadow, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, Andrew Nickel, Kyle E. Parcella, Kap-Sun Yeung, Louis S. Chupak
-
Patent number: 7741315Abstract: Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: GrantFiled: May 5, 2006Date of Patent: June 22, 2010Assignee: Merck Sharp & Dohme Corp.Inventors: Joseph P. Vacca, John S. Wai, Linda S. Payne, Richard C. A. Isaacs, Richard Pracitto
-
Publication number: 20100063068Abstract: The disclosure provides compounds of formula I, II, III, IV, and V, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.Type: ApplicationFiled: August 28, 2009Publication date: March 11, 2010Inventors: Richard Pracitto, John F. Kadow, John A. Bender, Brett R. Beno, Katharine A. Grant-Young, Ying Han, Piyasena Hewawasam, Andrew Nickel, Kyle E. Parcella, Kap-Sun Yeung, Louis S. Chupak
-
Publication number: 20090054399Abstract: Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: May 5, 2006Publication date: February 26, 2009Inventors: Joseph P. Vacca, John S. Wai, Linda S. Payne, Richard C.A. Isaacs, Wei Han, Melissa Egbertson, Richard Pracitto
-
Publication number: 20080261921Abstract: The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.Type: ApplicationFiled: April 10, 2008Publication date: October 23, 2008Applicant: SGX Pharmaceuticals, Inc.Inventors: Chixu Chen, Brian Eastman, Andreas Gosberg, Stefan N. Gradl, Gavin Hirst, Stephanie Hopkins, Khanh Thi Tuong Nguyen, Richard Pracitto, Paul E. Sprengeler, Ruo W. Steensma
-
Publication number: 20080176904Abstract: The present invention is directed to benzazole compounds which are potentiators of metabotropic glutamate receptors, including the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved.Type: ApplicationFiled: February 17, 2006Publication date: July 24, 2008Inventors: Steven P. Govek, Jean-Michel Vernier, Theodore Kamenecka, John H. Hutchinson, Richard Pracitto
-
Publication number: 20070213338Abstract: The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders—such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to ?2?-1 subunit of Ca channels.Type: ApplicationFiled: October 15, 2004Publication date: September 13, 2007Inventors: Alec Lebsack, Benito Munoz, Richard Pracitto, Shankar Venkatraman, Bowei Wang, Janet Gunzner
-
Publication number: 20070099950Abstract: The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders—such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to ?2?-1 subunit of Ca channels.Type: ApplicationFiled: November 18, 2004Publication date: May 3, 2007Inventors: Jongwon Lim, Julia Boueres, Benito Munoz, Richard Pracitto, Nicholas Stock, Shankar Venkatraman